News and press releases

How Biocogniv’s Agentic AI Process Increased Safety-Critical Software Development Velocity By More Than 10X

By enlisting many special-purpose AI agents that collaborate to produce safety-critical software, a team of two senior engineers was able to produce IEC 62304/ISO 13485-compliant artifacts in days instead of months.

January 14, 2026

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Biocogniv Achieves and Maintains ISO 13485:2016 Certification

The milestone underscores Biocogniv’s commitment to regulatory excellence as the company pursues FDA clearance for its product pipeline.

July 30, 2024

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Biocogniv Receives FDA Breakthrough Designation for Sepsis aiMarker™

The designation marks the company's first regulatory milestone.

April 7, 2023

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Biocogniv Powers UTMB’s Award-Winning COVID-19 Program

UTMB was recognized with a 2022 Gage Award for its COVID-19 Innovation by America’s Essential Hospitals.

July 27, 2022

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Biocogniv Featured in FastCompany Magazine

Read how Biocogniv's real-time, cloud-based platform clinOS™ was used by UTMB to power over 1 Million laboratory interpretations.

July 11, 2022

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Biocogniv Closes $6M in Seed Funding Led By Breyer Capital to Advance Digital Diagnostic Platform

Company Adds Multiple Healthcare Industry Leaders to Advisory Board

March 16, 2022

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Biocogniv Publishes Large Study on Sepsis aiMarker™

The study demonstrates the product's ability to detect sepsis before its onset.

October 1, 2021

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Biocogniv Develops AI-Based COVID-19 Diagnostic Tool

Using only routine blood tests, the tool can discriminate COVID-19 with high accuracy.

December 1, 2020

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.